News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
RXi Pharma (RXII) Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model 4/28/2016
Arrowhead Pharma (ARWR) Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARC-521 4/28/2016
Provectus Announces Publication Of Two Abstracts On Research Into IL PV-10 For Melanoma In Special Issue Of ANZ Journal Of Surgery 4/28/2016
Ocular Therapeutix (OCUL) Completes End-Of-Phase 2 Review With FDA For OTX-TP (Sustained Release Travoprost) For Glaucoma And Ocular Hypertension 4/28/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results 4/28/2016
Neovacs Obtains FDA Approval To Extend Its Phase IIb Clinical Trial In Lupus To United States 4/28/2016
Anavex (AVXL)’s Alzheimer’s Drug a Possible Game Changer After Patients Reported Remarkable Positive Response 4/27/2016
BioPharmX Reports Fourth Quarter and Fiscal Year End Financial Results 4/27/2016
Cumberland Pharmaceuticals (CPIX) Announces New Program To Develop Vasculan For Systemic Sclerosis 4/27/2016
Life Science Startup Company Strekin AG Announces The Launch Of A Phase 2 Clinical Study Of STR001 As A Potential New Treatment For Hearing Loss 4/27/2016
Berg Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer 4/27/2016
ABIVAX Abstract On ABX464 Selected For Presentation At The AIDS 2016 Conference In Durban, South Africa 4/27/2016
ThromboGenics NV (TBGNF) Release: New Ocriplasmin Research Findings Presented 4/27/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
Transition Therapeutics (TTH.TO) Announces Dosing Of First Patient In Phase 2 Study Of Drug Candidate TT701 4/26/2016
Synthetic Biologics (SYN) To Report First Quarter 2016 Operational Highlights And Financial Results On May 5, 2016 4/26/2016
Asterias Biotherapeutics To Present At Stem Cell Summit 2016 4/26/2016
AM-Pharma Receives FDA Fast Track Designation For Recap In Acute Kidney Injury 4/26/2016
Clearside Biomedical Announces Positive Preliminary Phase 2 Results In Patients With Macular Edema Associated With Retinal Vein Occlusion 4/26/2016
Alizé Pharma Reports Positive Results From Its Phase II Clinical Trial Of AZP-531 In Prader-Willi Syndrome 4/26/2016
Akebia (AKBA) Announces Presentation Of Vadadustat Phase 2 Dialysis Data At Upcoming National Kidney Foundation 2016 Spring Clinical Meetings 4/26/2016
Celator Pharma (CPXX) Announces Positive Results Demonstrating Reduced Healthcare Resource Use With VYXEOSTM Compared To Standard Treatment For Acute Myeloid Leukemia (AML) 4/25/2016
BioPharmX Announces Full Patient Enrollment In Phase 2a Study Of BPX-01 Topical Antibiotic For Acne 4/25/2016
AbGenomics International Announces Promising Final Results From Their Phase II Open-Label Clinical Study Of Abgn-168H/Neihulizumab In Psoriatic Arthritis, A T-Cell Mediated Disease 4/25/2016
Xencor To Host First Quarter 2016 Financial Results Webcast And Conference Call On May 2, 2016 4/25/2016
Cerulean Pharma Inc. (CERU) To Host First Quarter 2016 Conference Call On May 2 4/25/2016
Helix Biopharma (TSX:HBP) Release: Trial Steering Committee Recommends Initiation Of Phase II L-DOS47 Study In Non-Small Cell Lung Cancer 4/25/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
Tobira Announces Upcoming Presentations On Biomarkers For NASH At Two Scientific Meetings 4/22/2016
NeuralStem Inc. Receives NASDAQ Notice Of Bid Price Deficiency 4/22/2016
Galapagos (GLPG.BR) Reports Additional Data With Filgotinib From The Phase 2 FITZROY Study 4/22/2016
Kerastem Hair Growth Clinical Trial Update 4/22/2016
Novartis AG (NVS)'s Breakthrough Muscle Drug Fails to Meet Primary Goal in Patients with sIBM 4/21/2016
Eiger Biopharma Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb (BMY) 4/21/2016
DelMar Pharma Release: FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer 4/21/2016
Leading Biosciences Announces Issuance Of U.S. Patent For Lead Clinical Asset LB1148 4/21/2016
TapImmune (TPIV) Announces Phase 2 Ovarian Cancer Trial Study With AstraZeneca PLC (AZN)/MedImmune (AZN) And Sloan Kettering Cancer Institute 4/21/2016
FibroGen, Inc. (FGEN) Release: Promising Phase II Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 4/21/2016
Fibrocell Science, Inc. Announces Last Patient Visit For Primary Endpoint Analysis In Phase II Clinical Trial Of Azficel-T For The Treatment Of Vocal Cord Scarring 4/21/2016
Acorda (ACOR)'s Parkinson’s Candidate Meets Goal in Phase II Trial 4/20/2016
bluebird bio (BLUE) Stock Falls on Starbeam Interim Data 4/20/2016
CytRx (CYTR) To Present Updated Aldoxorubicin Clinical Trial Data At The ASCO Annual Meeting In June 2016 4/20/2016
X4 Pharma Announces Data Presentation For Lead Candidate X4P-001 At AACR Annual Meeting 4/20/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/20/2016
Omeros Corporation (OMER) Release: Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases 4/20/2016
vTv Therapeutics Presents Data On Two Diabetes Candidates At Keystone Symposia On New Therapeutics For Diabetes And Obesity 4/20/2016
Ionis Pharma (IONS) Reports Data Update From Nusinersen Phase 2 Study In Infants With Spinal Muscular Atrophy And Reviews Neurological Disease Franchise 4/20/2016
Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Multiple Drug Combination Strategies Due To The Targeting Of MCL-1 4/20/2016
Spectrum Pharma (SPPI) Release: FDA Grants Orphan Drug Exclusivity To EVOMELA (melphalan) For Injection, Indicated For Multiple Myeloma 4/20/2016
Alnylam (ALNY) Reports Complete 18-Month Data From Ongoing Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN) 4/20/2016
Investors Relieved as bluebird bio (BLUE)'s Early Data from Rare Disease Study Looks Positive 4/20/2016
Sucampo (SCMP) to Terminate Development of Cobiprostone for for PPI-Refractory NERD/SGERD After Trial Failure 4/19/2016
DelMar Pharma Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At AACR Annual Meeting 4/19/2016
RXi Pharma (RXII) Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109 4/19/2016
BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016 4/19/2016
CardioCell Completes Enrollment For A Phase IIa Clinical Trial Using Its Stem Cells For Participants With Chronic Heart Failure 4/19/2016
Sangamo (SGMO) Announces Presentations On ZFP Therapeutic Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy 4/19/2016
Celator Pharma (CPXX) Reports On Previously Suspended Investigator-Initiated Clinical Study 4/19/2016
Dynavax (DVAX) Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101 4/19/2016
Immune Pharma Release: New Biomarker Data To Be Presented At AACR Helps Predict Overall Survival In Patients With Acute Myeloid Leukemia (AML) Treated With Ceplene And Low-Dose IL-2 Immunotherapy, Including Those Over 60 Years Of Age 4/19/2016
SpinalCyte, LLC Announces Final Results From Phase II Animal Trials Using Human Dermal Fibroblast Transplantation For Intervertebral Disc Degeneration 4/19/2016
ABIVAX Obtains Regulatory And Ethics Clearance In Spain To Begin Second Phase IIa Clinical Trial For ABX464 In HIV/AIDS Patients 4/19/2016
Cerulean Pharma Inc. (CERU) Announces Presentation At 2016 AACR Annual Meeting Of Stage 1 Data From Phase 2 Trial In Platinum-Resistant Ovarian Cancer 4/19/2016
Acucela Announces End Of Treatment Period In Phase 2b/3 Clinical Trial Of Emixustat Hydrochloride 4/19/2016
Biothera Presents New Cancer Immunotherapy Research At The 2016 AACR Annual Meeting 4/19/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
AbbVie (ABBV)'s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial 4/18/2016
Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration 4/18/2016
SAGE Therapeutics (SAGE) Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting 4/18/2016
MorphoSys AG Licensing Partner GlaxoSmithKline (GSK) Starts Phase 2 Study With GSK3196165 (MOR103) In Hand Osteoarthritis 4/18/2016
Conatus Pharma Late Breaker Oral Presentation At EASL Details Phase II Liver Cirrhosis Trial Three-Month Data 4/18/2016
ARCA biopharma Announces 75th Patient Enrolled In GENETIC-AF Phase IIB/III Clinical Trial 4/18/2016
SAGE Therapeutics (SAGE) Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy of Neurology Annual Meeting 4/18/2016
Enanta Pharmaceuticals, Inc. Announces New Data From AbbVie (ABBV)’s SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus 4/18/2016
Nordic Nanovector: Betalutin Continues To Show Promising Efficacy And Increasing Duration Of Response (DoR) 4/18/2016
Multiple Myeloma Phase II Study Of BioInvent (BOVNF)'s Antibody BI-505 Ready To Start 4/18/2016
Bristol-Myers Squibb (BMY) Release: First Presentation Of Two-Year Overall Survival Data For Opdivo (Nivolumab) In Combination With Yervoy (Ipilimumab) Showed Superior Efficacy Versus Yervoy Alone In Advanced Melanoma 4/18/2016
Adaptive Biotech And Collaborators To Present 10 Studies Demonstrating The Utility Of Immunosequencing In Both Tissue And Blood Samples At 2016 AACR Annual Meeting 4/18/2016
AstraZeneca PLC (AZN) Presents DNA Damage Response Science At The AACR 2016 Annual Meeting 4/18/2016
Gilead (GILD) Presents New Data Highlighting Progress In Liver Fibrosis 4/18/2016
AbbVie (ABBV)'s Hep C Therapy ABT-493 and ABT-530 Show Promise in Pre-Treated Patients 4/15/2016
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV)’s Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals 4/15/2016
Regulus (RGLS) Presents Additional Interim Data On RG-101 At International Liver Congress (ILC 2016) 4/15/2016
Ionis Pharma (IONS) Highlights Antisense Drugs To Treat Neurological Diseases At The American Academy of Neurology Meeting 4/15/2016
Ariad (ARIA) Presents Updated Phase 1/2 Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/15/2016
Trevena (TRVN) Announces BLAST-AHF Phase 2b Trial Results Will Be Presented At The Heart Failure 2016 Conference 4/15/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Updated Data From Randomized Phase 2 Study Of REOLYSIN In Pancreatic Cancer 4/14/2016
Soligenix (SNGX) Announces Issuance Of New Patents For Dusquetide 4/14/2016
Viking Therapeutics (VKTX) Announces Closing Of Public Offering Of Common Stock And Warrants 4/14/2016
Clementia Release: Positive Effects Of Palovarotene On Spontaneous Heterotopic Ossification, Mobility, And Skeletal Growth In Mouse Models Of FOP Reported In Journal Of Bone And Mineral Research 4/14/2016
Pharma Mar Will Be Present At The 2016 Annual AACR Congress With The Latest Novelties In Its Compounds Of Marine Origin In Solid And Hematological Tumors 4/14/2016
Puma Biotech (PBYI)’s Nefert-T Phase II Study Published Online In JAMA Oncology 4/14/2016
Wilson Therapeutics Presents Data On Decuprate (WTX101) From Ongoing Phase 2 Study At The International Liver Congress 2016 4/14/2016
Burzynski Research Institute Announces The Launch Of A New Clinical Trial In Diffuse Intrinsic Brainstem Glioma 4/14/2016
Repros Therapeutics (RPRX) Skyrockets Premarket Following Positive Clinical Data for Vaginal Proellex 4/13/2016
Mast Therapeutics (MSTX) Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network 4/13/2016
Boehringer Ingelheim Release: Head-To-Head Study Demonstrating Gilotrif (Afatinib) Significantly Improved Clinical Outcomes Compared To Iressa (Gefitinib) In EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Published In The Lancet Oncology 4/13/2016
Therabron Receives Notice Of Allowance For New Patent Supporting The Recombinant CC10 Technology Platform 4/13/2016
Tocagen Inc. To Present Data From Clinical Trials And Preclinical Programs At Four Scientific Conferences 4/13/2016
Innate Immunotherapeutics Announces Clinical Trial Fully Enrolled And Receives Strong Interest From Potential Pharma Partners 4/13/2016
Lumicell Successfully Completes Phase 2a Feasibility Study 4/13/2016
107th Annual Meeting Of AACR: Bayer (BAY) To Present New Data On Advancing Oncology Portfolio 4/13/2016
Struggling Ariad (ARIA)'s Luck Might be Turning Around as Company Eyes Pfizer (PFE)'s ALK Space 4/13/2016
Celsion (CLSN) Announces Upcoming Presentation At AACR 2016 Highlighting Potential Of GEN-1 IL-12 Immunotherapy In Ovarian Cancer 4/12/2016
RedHill Biopharma (RDHL) Initiates Phase II Study Of BEKINDA For Irritable Bowel Syndrome 4/12/2016
Catabasis Pharma Initiates Part B Of The MoveDMD Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 4/12/2016
Cell And Gene Therapy Catapult, UCLB And Imperial Innovations Announce Positive Interim Review In Ongoing AML WT1 T Cell Clinical Trial 4/12/2016
Adocia Initiates A Phase 1/2 Clinical Trial On The Post-Meal Effect Of Rapid-Acting Human Insulin, HinsBet U100 4/12/2016
Cerecor Inc. Announces $1.0 Million Research & Development Grant From The National Institute on Drug Abuse (NIDA) At The NIH 4/11/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
ORYZON Genomics Release: Data On ORY-1001 To Be Presented At The AACR Annual Meeting 2016 In New Orleans 4/11/2016
Inotek Pharmaceuticals Corporation (ITEK) Announces The Journal Of Ocular Pharmacology And Therapeutics Has Published Its Phase 2 Data For Trabodenoson In Patients With Glaucoma And Ocular Hypertension 4/11/2016
Aimmune (AIMT) Presents Data On Biomarkers And Potential To Predict Response To Peanut Allergy Treatment With AR101 4/11/2016
Tyme Reports Year-End Financial Results For 2015 4/11/2016
AstraZeneca PLC (AZN), Eli Lilly (LLY) Alzheimer's Drug Enters Final Testing Stage, Astra Earns $100 Million 4/8/2016
Debiopharm To Present The Latest Findings On Debio 1450 At ECCMID 4/8/2016
3 Biotechs Getting Another Shot After Failed Trials 4/7/2016
Shift in R&D Strategy Forces BIND Therapeutics (BIND) to Slash 38% of Workforce, Look for New Capital and Deals 4/7/2016
Galapagos (GLPG.BR) Initiates A Phase IIa Study With GLPG1690 In Idiopathic Pulmonary Fibrosis Patients 4/7/2016
TapImmune (TPIV) Completes GMP Manufacturing And Release Of TPIV 200 Vaccine 4/7/2016
Portage Biotech Announcing Results Of Its Annual Shareholder Meeting And Other Corporate Matters 4/7/2016
Acorda (ACOR) Release: Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy of Neurology Annual Meeting 4/7/2016
SanBio, Inc. Release: Clinical Trial Involving Regenerative Cell Treatment For Patients With Traumatic Brain Injury Permitted In Japan 4/6/2016
MorphoSys AG Initiates Phase 2 Combination Trial Of MOR208 And Lenalidomide In Patients With Relapsed Or Refractory Diffuse Large B Cell Lymphoma (DLBCL) 4/6/2016
Kamada Ltd. (KMDA) Announces Initiation Of Phase 2 Clinical Trial With Intravenous Alpha-1 Antitrypsin For The Prevention Of Lung Transplant Rejection 4/6/2016
Vericel (ASTM)'s Stem Cell Heart Failure Therapy Cuts Deaths 4/5/2016
Oramed (ORMP) Completes Phase IIb Oral Insulin Study 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) To Present At Needham Healthcare Conference 4/5/2016
Ironwood (IRWD) Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis 4/5/2016
RedHill Biopharma (RDHL) Announces Interim Results From Phase IIa Proof-Of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis 4/5/2016
Newron Pharma (NWRN) Release: Ongoing Phase II Study Of Evenamide (NW-3509) May Suggest An Alternative Approach To The Treatment Of Schizophrenia 4/5/2016
Rich Pharma Retains Contract Research Organization, CMIC, To Manage Upcoming Phase 1/2 Clinical Trial For Its Acute Myelocytic Leukemia (AML) And Myelodysplastic Syndrome (MDS) Drug In Thailand 4/4/2016
Motus Completes Enrollment Of Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/4/2016
Biomarker Analyses Of Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Data Demonstrate Potential For Treating ALS Patients With Systemic Inflammation 4/4/2016
Neuraltus Pharmaceuticals, Inc. Announces Plans For Second Phase 2 Study Of NP001 In ALS Using Biomarker For Enriched Patient Selection 4/4/2016
Capricor Therapeutics, Inc. Announces DSMB Recommends Continuation Of HOPE-Duchenne Clinical Trial 4/4/2016
Motus Presents Clinical Proof-Of-Concept Results For Relamorelin In The Treatment Of Anorexia 4/4/2016
Flexion (FLXN) Announces Presentation Of Results From Pivotal Phase IIb And Phase III Clinical Trials For Zilretta At Osteoarthritis Research Society International (OARSI) 2016 World Congress 4/4/2016
Cytokinetics (CYTK) Announces Start Of Phase II Clinical Trial Of Omecamtiv Mecarbil In Japanese Subjects With Heart Failure 4/4/2016
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College of Cardiology 65th Annual Scientific Sessions & Expo 4/4/2016
ContraVir Invited To Present CMX157 Data At The Oligonucleotide Therapeutics & Delivery Conference 4/4/2016
Probiodrug AG Announces Results Of Chronic Toxicology Studies With PQ912, Its "First In Class" Glutaminyl Cyclase (QC) Inhibitor For The Treatment Of Alzheimer’s Disease 4/4/2016
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On April 4-6, 2016 In Stockholm, Sweden 4/4/2016
uniQure (QURE) Announces Results For Fourth Quarter And Financial Year 2015 4/4/2016
Ascendis Pharma A/S Announces TransCon Growth Hormone Oral And Poster Presentations At ENDO 2016 4/4/2016
Kiadis Pharma Presents Positive Data On The Primary Endpoint Of Its Single Dose Phase II Trial With ATIR101 4/4/2016
Alexion (ALXN) Release: Data Presented At ENDO 2016 Show Sustained Improvements In Survival Rates, Bone Healing, Respiratory Support And Physical Function In Children With Hypophosphatasia (HPP) Receiving Long-Term Treatment With Strensiq (Asfotase Alfa) 4/4/2016
ORYX Enrolls First Patients In A Dose-Escalating Phase I/IIa Pilot Study With Oncolytic Virus Parvoryx To Treat Metastatic Pancreatic Cancer 4/4/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry 4/4/2016
Can-Fite BioPharma (CFBI) Reports 2015 Financial Results & Provides Clinical Pipeline Update 4/1/2016
Genocea (GNCA) Stock Doubles After Market Yesterday on Positive 12 Months Genital Herpes Data 4/1/2016
Senhwa Biosciences Release: FDA Approves Clinical Trial Application (CTA) For Phase I/II Clinical Trial Of CX-5461 In Solid Tumors And Breast Cancers 4/1/2016
Asterias Biotherapeutics Announces Record Date For Distribution Of Warrants To Holders Of Asterias Series A Common Stock 4/1/2016
MediGene AG (MDGEF.PK) Announces Start Of Phase II Trial With DC Vaccines And Upcoming Milestone Payment 4/1/2016
SELLAS Life Sciences To Present Phase II Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting And The <>13th International Conference Of The International Mesothelioma Interest Group (IMig) 4/1/2016
ArmaGen Technologies, Inc. Announces Initiation Of Phase 2 Proof-Of-Concept Clinical Trial In Brazil To Study AGT-181 For The Treatment Of Hurler Syndrome 3/31/2016
aTyr Pharma Announces Encouraging Phase 1b/2 Results For Resolaris In Its First Rare Myopathy Trial 3/31/2016
RXi Pharma (RXII) Reports Fourth Quarter And Year End 2015 Financial Results And Recent Corporate Highlights 3/31/2016
Tobira Therapeutics Inc. Release: Independent Research To Be Presented At International Liver Congress Shows Cenicriviroc Improves Steatohepatitis And Liver Fibrosis In NASH Model 3/31/2016
aTyr Pharma Announces Fourth Quarter 2015 Operating Results 3/31/2016
StemCells (STEM) Pathway Study In Cervical Spinal Cord Injury Featured In The Downey Patriot 3/31/2016
GENFIT (ALGFT) To Begin Elafibranor Clinical Program In PBC 3/31/2016
Celimmune Commences Screening In Phase 2 Clinical Study In Refractory Celiac Disease Type II 3/31/2016
Celsion (CLSN) Reports Year End 2015 Financial Results And Provides Business Update 3/30/2016
Tokai Pharmaceuticals (TKAI) Announces Dosing Of First Patient In Phase 2 Expansion Study Of Galeterone In Enzalutamide-Refractory mCRPC Patients 3/30/2016
Janssen To Unveil New Hepatitis B And C Data At The International Liver Congress 2016 Of The European Association For The Study Of The Liver (EASL) 3/30/2016
Rich Pharma Further Extends CRO Agreement With Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial For Its Acute Myelocytic Leukemia (AML) And Myelodysplastic Syndrome (MDS) Drug In The United States 3/30/2016
Renova Therapeutics Release: The JAMA Cardiology Publishes Phase 2 Results Of AC6 Gene Transfer In Patients With Heart Failure 3/30/2016
BioLineRx Ltd. Reports Successful Top-Line Results In Phase 2 Trial For AML 3/29/2016
Caladrius Biosciences (CLBS) Announces First Subject Treated In CLBS03 Type 1 Diabetes Phase II Trial 3/29/2016
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Provides Fourth Quarter And Year-End 2015 Financial Results 3/29/2016
Kiadis Pharma To Host A Webcast Of The Full Dataset On The Primary Endpoint Of Its Single-Dose Phase II Trial With ATIR101 3/29/2016
Bone Therapeutics Reports Initial Efficacy Results From Its PREOB Phase IIA Trial In Severe Osteoporosis 3/29/2016
SpinalCyte, LLC Announces New Results From Phase II Animal Trials Of Cell Therapy To Regenerate The Spinal Disc 3/29/2016
Aurinia (ISA.TO) Announces Result From Data And Safety Monitoring Board For Its Phase 2b Study In Lupus Nephritis -- Study To Continue As Planned 3/29/2016
Alder Biopharma's Migraine Drug Meets Primary and Secondary Endpoints in Phase 2b Trial 3/28/2016
Apricus Biosciences (APRI)'s Fispemifene Missed Primary, Secondary Objectives in Phase IIb Study 3/28/2016
Eiger Biopharma Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency 3/28/2016
CASI Pharmaceuticals  (CASI) Reports 2015 Fourth Quarter And Full Year Financial Results 3/28/2016
BiondVax Pharmaceuticals's Universal Flu Vaccine Phase 2b Clinical Trial Recruitment Complete 3/28/2016
Vericel (ASTM) Announces Publication Of Clinical Trial Rationale And Study Design For The Phase IIb Ixcell-DCM Trial Of Ixmyelocel-T In Patients With Heart Failure Due To Ischemic Dilated Cardiomyopathy 3/28/2016
Neothetics (NEOT) Provides Update And Plan Forward For LIPO-202 Program 3/28/2016
XBiotech Advances To Phase II Portion Of Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 3/28/2016
Aerie (AERI) Initiates Second Phase 3 Registration Trial Of Roclatan (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% 3/28/2016
Solasia Pharma K.K. Initiates Phase 2 Study Of Darinaparsin (SP-02) For Peripheral T-Cell Lymphoma 3/28/2016
OXIS International, Inc. (OXIS) Continues Push For Zika Cure, Following New Confirmed Case In South Korea 3/28/2016
DelMar Pharma Announces Abstract Presentations For The AACR Annual Meeting In April 2016 3/24/2016
Living Cell Tech Starts Phase IIb Clinical Trial Of NTCELL For Parkinson’s Disease 3/24/2016
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2015 Financial Results 3/24/2016
InfaCare Pharmaceutical Corporation Announces The Successful Completion Of Its Phase IIB Multicenter Development Program For Stannsoporfin 3/24/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015 3/24/2016
BioLineRx Ltd. Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment 3/23/2016
Asterias Biotherapeutics To Report Fourth Quarter And Full Year 2015 Results On March 29, 2016 3/23/2016
Celsion (CLSN) To Hold Year-End 2015 Financial Results Conference Call On Wednesday, March 30, 2016 3/23/2016
Ironwood (IRWD) Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease 3/23/2016
Newron Pharmaceuticals (NWRN) Release: Evenamide (NW-3509): Evidence Of Anti-Psychotic Efficacy As An Add-On To Antipsychotics In Ongoing Phase 2 Study May Suggest An Alternative Approach To The Treatment Of Schizophrenia 3/23/2016
Three Big Obstacles Bay Area's Raptor (RPTP) Needs to Overcome 3/22/2016
e-Therapeutics Strategic Prioritization On Discovery Platform And Commercialisation 3/22/2016
Kadmon Announces Publication Of Data Demonstrating The Potential Of ROCK2 Inhibition To Treat Chronic Graft-Versus-Host Disease 3/22/2016



//-->